Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 9/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21226122 | 1.00 | GNAI3 (0.39) | GNAI3GNAO1GNAI1DNM1 | |
| SCHEMBL24822691 | 1.00 | GNAI3 (0.39) | GNAI3GNAO1GNAI1DNM1 | |
| Iodide SCHEMBL15008302 | 0.98 | GNAI3 (0.38) | GNAI3GNAO1GNAI1DNM1 | |
| Iodide SCHEMBL15008368 | 0.98 | GNAI3 (0.38) | GNAI3GNAO1GNAI1DNM1 | |
| Iodide SCHEMBL15008673 | 0.98 | GNAI3 (0.38) | GNAI3GNAO1GNAI1DNM1 | |
| Iodide SCHEMBL15008245 | 0.98 | GNAI3 (0.38) | GNAI3GNAO1GNAI1DNM1 | |
| Iodide SCHEMBL15008388 | 0.98 | GNAI3 (0.38) | GNAI3GNAO1GNAI1DNM1 | |
| Iodide SCHEMBL15008980 | 0.98 | GNAI3 (0.38) | GNAI3GNAO1GNAI1DNM1 | |
| Iodide SCHEMBL15008878 | 0.96 | GNAI3 (0.35) | GNAI3GNAO1GNAI1 | |
| Iodide SCHEMBL15008323 | 0.91 | KCNH2 (0.33) | GNAI3GNAO1GNAI1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | GNAI3 656/4885GNAO1 534/4885GNAI1 664/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | GNAI3 656/4885GNAO1 534/4885GNAI1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.